{"id":"desloratadine-given-orally","safety":{"commonSideEffects":[{"rate":"12-16%","effect":"Headache"},{"rate":"2-3%","effect":"Somnolence"},{"rate":"2-3%","effect":"Fatigue"},{"rate":"3-5%","effect":"Dry mouth"},{"rate":"2-4%","effect":"Pharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Desloratadine competitively binds to peripheral H1 receptors on mast cells and basophils, preventing histamine release and its downstream effects on smooth muscle contraction, vasodilation, and itching. As a non-sedating antihistamine, it has minimal blood-brain barrier penetration due to its molecular structure and efflux by P-glycoprotein, resulting in reduced central effects compared to first-generation antihistamines.","oneSentence":"Desloratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:06.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic idiopathic urticaria"}]},"trialDetails":[{"nctId":"NCT05232825","phase":"PHASE3","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-03","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":236},{"nctId":"NCT01916967","phase":"PHASE3","title":"An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-08-27","conditions":"Urticaria","enrollment":239}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Desloratadine given orally","genericName":"Desloratadine given orally","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desloratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration. Used for Allergic rhinitis (seasonal and perennial), Chronic idiopathic urticaria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}